Barinthus Biotherapeutics plc annual r&d spending
2020
2021
2022
2023
2024
2025
Barinthus Biotherapeutics plc R&D Spending Growth & History (BRNS)
Barinthus Biotherapeutics plc's r&d spending was $25.6M for fiscal 2025.
View full Barinthus Biotherapeutics plc company overviewBarinthus Biotherapeutics plc annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.6M | −$16.7M | −39.47% |
| 2024 | 2024-12-31 | $42.2M | −$2.6M | −5.88% |
| 2023 | 2023-12-31 | $44.9M | $2.5M | +5.96% |
| 2022 | 2022-12-31 | $42.4M | $22.0M | +107.89% |
| 2021 | 2021-12-31 | $20.4M | $6.0M | +41.59% |
| 2020 | 2020-12-31 | $14.4M | — | — |
Barinthus Biotherapeutics plc quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.9M | −$4.0M | −50.67% |
| Q1 2026 | 2026-03-31 | $3.6M | −$4.7M | −56.66% |
| Q4 2025 | 2025-12-31 | $3.9M | −$4.4M | −52.70% |
| Q3 2025 | 2025-09-30 | $5.4M | −$5.7M | −51.61% |
| Q2 2025 | 2025-06-30 | $8.0M | −$3.7M | −31.80% |
| Q1 2025 | 2025-03-31 | $8.3M | −$2.8M | −25.48% |
| Q4 2024 | 2024-12-31 | $8.3M | $1.9M | +30.39% |
| Q3 2024 | 2024-09-30 | $11.1M | −$4.0M | −26.45% |
| Q2 2024 | 2024-06-30 | $11.7M | −$1.9M | −13.89% |
| Q1 2024 | 2024-03-31 | $11.1M | $1.3M | +13.36% |
| Q4 2023 | 2023-12-31 | $6.4M | −$5.8M | −47.70% |
| Q3 2023 | 2023-09-30 | $15.1M | $5.4M | +55.42% |
| Q2 2023 | 2023-06-30 | $13.5M | $3.8M | +39.33% |
| Q1 2023 | 2023-03-31 | $9.8M | −$887,000 | −8.29% |
| Q4 2022 | 2022-12-31 | $12.2M | $5.3M | +77.08% |
| Q3 2022 | 2022-09-30 | $9.7M | $5.4M | +122.92% |
| Q2 2022 | 2022-06-30 | $9.7M | $5.2M | +115.57% |
| Q1 2022 | 2022-03-31 | $10.7M | $6.1M | +132.13% |
| Q4 2021 | 2021-12-31 | $6.9M | $4.3M | +168.16% |
| Q3 2021 | 2021-09-30 | $4.4M | $669,000 | +18.07% |
| Q2 2021 | 2021-06-30 | $4.5M | $632,000 | +16.30% |
| Q1 2021 | 2021-03-31 | $4.6M | $368,000 | +8.68% |
| Q4 2020 | 2020-12-31 | $2.6M | — | — |
| Q3 2020 | 2020-09-30 | $3.7M | — | — |
| Q2 2020 | 2020-06-30 | $3.9M | — | — |
| Q1 2020 | 2020-03-31 | $4.2M | — | — |
Barinthus Biotherapeutics plc r&d spending trends
Over the last five fiscal years, Barinthus Biotherapeutics plc's r&d spending increased from $14.4M to $25.6M, a change of $11.2M. The latest reported quarter, Q2 2026, shows $3.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Barinthus Biotherapeutics plc source filings ↗